27.07.2011 • News

Merck KGaA Slips To Loss In Q2; Trims FY11 Profit Forecast

German drug manufacturer Merck KGaA reported Wednesday that its second-quarter net loss attributable to the company was €85.9 million or €0.40 per share, compared to prior year's profit of €183.4 million or €0.84 per share.

Core earnings per share, which excluded certain one-time items, declined 39.7% to €0.94 from €1.56 last year.

Total revenues increased 15.7% to €2.56 billion from €2.21 billion a year ago.

For the quarter, core operating result declined from last year, while underlying core operating result grew to €548 million from €501 million in 2010.

Looking ahead for fiscal 2011, the company now projects total revenues will increase to between €10 billion and €10.4 billion. The group operating result for 2011 is expected to amount to about €1 billion, which is below the guidance given in April primarily due to the many one-time adjustments.
The company's previous forecast for total revenues was a growth of 10 -15%.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read